Print

AVEG 018

A Phase I Safety and Immunogenicity Study Trial of UBI Microparticulate Monovalent HIV-1 MN Peptide Immunogen in HIV-1 Seronegative Human Subjects

Trial Details:

I Completed
National Institute of Allergy and Infectious Diseases (NIAID) June 27, 1994
UBI HIV-1 Peptide Vaccine, Microparticulate Monovalent Env V3 loop gp120 B MN
UBI HIV-1 Peptide Vaccine, Microparticulate Monovalent Protein
USA 32
NCT00000798
http://clinicaltrials.gov/ct2/show/NCT00000798